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ABSTRACT
One of the factors proposed as mediators of vascular dysfunction observed in diabetes is the increased generation of reactive oxygen 
species (ROS). This provides support for the use of antioxidants as early and appropriate pharmacological intervention in the develop-
ment of late diabetic complications. In streptozotocin (STZ)-induced diabetes in rats we observed endothelial dysfuction manifested 
by reduced endothelium-dependent response to acetylcholine of the superior mesenteric artery (SMA) and aorta, as well as by 
increased endothelaemia. Changes in endothelium-dependent relaxation of SMA were induced by injury of the nitric oxide radical 
(•NO)-signalling pathway since the endothelium-derived hyperpolarising factor (EDHF)-component of relaxation was not impaired 
by diabetes. The endothelial dysfunction was accompanied by decreased •NO bioavailabity as a consequence of reduced activity of 
eNOS rather than its reduced expression. The results obtained using the chemiluminiscence method (CL) argue for increased oxidative 
stress and increased ROS production. The enzyme NAD(P)H-oxidase problably participates in ROS production in the later phases of 
diabetes. Oxidative stress was also connected with decreased levels of reduced glutathione (GSH) in the early phase of diabetes. After 
10 weeks of diabetes, adaptational mechanisms probably took place because GSH levels were not changed compared to controls. 
Antioxidant properties of SMe1EC2 found in vitro were partly confirmed in vivo. Administration of SMe1EC2 protected endothelial func-
tion. It significantly decreased endothelaemia of diabetic rats and improved endothelium-dependent relaxation of arteries, slightly 
decreased ROS-production and increased bioavailability of •NO in the aorta. Further studies with higher doses of SMe1EC2 may clarify 
the mechanism of its endothelium-protective effect in vivo.
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hyperpolarising factor (EDHF) (Vanhoutte and Mombouli, 
1996; Shimokawa, 1999). Endothelial dysfunction partici-
pates in the pathophysiology of various diseases like ath-
erosclerosis, essential hypertension, diseases connected 
with ischaemia/reperfusion (I/R), rheumatoid arthritis, 
diabetic micro- and macrovasculopathies, etc. Among 
the mechanisms of the vascular dysfunction observed in 
these diseases, increased generation of reactive oxygen 
species (ROS) is emerging as a crucial factor. This pro-
vides support for the use of antioxidants in preventing or 
alleviating the above mentioned diseases.
In the last decades, more than 7 0 new derivatives  
(Štolc et al., 2010) of the pyridoindole antioxidant sto-
badine – (–)-cis-2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-
1H-pyrido[4,3-b]indole, (Štolc et al., 1983; Horáková and 
Štolc, 1998) were synthesised and tested in the Institute 
Introduction
In the last decades, scientific research has revealed that 
deterioration of the endothelium with subsequent dam-
age of smooth muscle reactivity results in generalised 
increase in vascular tone, platelet aggregation, thrombus 
formation, etc. The endothelium plays an important role 
in maintaining vascular homeostasis by synthesising and 
releasing several vasodilators, including prostacyclin, 
nitric oxide radical  (NO), and endothelium-derived 
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of Experimental Pharmacology and Toxicology, Slovak 
Academy of Sciences. The main reason for synthesising 
new derivatives was to enlarge the antioxidative and anti-
radical capacity of the parent substance and to eliminate 
the undesired α1-adrenolytic activity of stobadine (Štolc et 
al., 2006). SMe1EC2, one of these new compounds, exhib-
ited an increase in its antioxidative activity achieved by 
substitution of the methyl group in position 8 of stobadine 
by a methoxy group. This is explained by the increased 
ability of the aromatic circle to delocalise electron density 
from the stable nitrogen radical on indole. Substitution 
of nitrogen on the piperidine circle by an ethoxycarbonyl 
group prevented protonisation of this atom and led to loss 
of undesirable α1-adrenolytic activity and to decreased 
toxicity of SMe1EC2 (Štolc et al., 2010; Štolc et al., 2006; 
Májeková et al., 2006, Ujházy et al., 2008). This was 
the reason why we selected this compound to study the 
possibility to improve endothelial dysfunction in several 
experimental models. 
In our previous works, we documented endothelial 
dysfunction induced by different pathological situations 
in experimental models of ischaemia/reperfusion (I/R) 
(Sotníková et al., 1998; Nosáľová et al., 2004; Szöcs, 2004; 
Sotníková et al., 2005; Nosáľová et al., 2007), adjuvant 
arthrithis (Sotníková et al., 2009), in spontaneously hyper-
tensive rats in conditions of social stress (Sotníková et al., 
2006; 2007), in hypertriglyceridaemic rats (Sotníková 
et al., 2008), etc. The common feature proved to be 
impaired endothelium-dependent relaxation of the arter-
ies manifested by decreased response to acetylcholine. In 
the model of I/R of the abdominal aorta, we demonstrated 
I/R-induced reversible ultrastructural changes both in 
endothelial and smooth muscle cells, predominantly in 
the mitochondria. Participation of ROS in vascular injury 
was confirmed directly on using oxidative fluorescent 
microtopography (Szöcs et al., 2003), by observation 
of increased lipid peroxidation in homogenates of I/R 
aortae and by the ability of the antioxidant stobadine to 
protect the abdominal aorta against I/R-induced changes 
(Sotníková et al., 1998). Further, decreased release of NOx 
and increased activity of lysosomal enzymes – N-acetyl-β-
D-glucosaminidase (NAGA) and acid phosphatase (APH) 
– in aortic homogenates were observed (Sotníková et al., 
1999). Lysosomes consist of a lipoprotein membrane sur-
rounding potent acid hydrolases able to degrade all known 
constituents of cells. Leakage of lysosomal enzymes into 
cells and the surrounding extracellular space has been 
implicated in the pathogenesis of tissue injury (Waters et 
al., 1992). Pretreatment of rats with stobadine reduced the 
NAGA and APH release evoked by I/R (Sotníková et al., 
1997, Navarová et al., 1998).
The use of the model of mesenteric I/R in rats provided 
evidence of ROS contribution to I/R-induced endothelial 
dysfunction. By the method of luminol enhanced chemi-
luminiscence (CL) we demonstrated increased generation 
of ROS in SMA tissue after 60-min ischaemia followed by 
30-min reperfusion of the rat mesentery, which resulted 
in injury of both the NO and EDHF-endothelial relaxing 
systems of the SMA (Sotníková et al., 2005).
Endothelial dysfunction in 
experimental diabetes
Although the aetiology of vascular disorders in long last-
ing diabetes is not fully understood, it has been suggested 
that abnormal vascular function may underlie many of the 
associated vasculopathies. These are major causes of dis-
ability and death in patients with diabetes mellitus (Yan 
et al., 2003). Under physiological conditions, glucose is 
transported into the cells by means of glucose transport-
ers. Transport of glucose to the endothelium and smooth 
muscle cells is not insulin-dependent, thus in the case of 
hyperglycaemia intracellular concentration of glucose in 
these cells increases and can induce their injury. 
Reduction in endothelium-dependent relaxation is 
a common feature known to occur in both conduit and 
resistance arteries of experimental diabetic animals. 
Moreover, increased responsiveness of vessels to contrac-
tile agents in diabetes mellitus was also reported. Among 
the proposed mechanisms of vascular dysfunction in 
diabetes, the increased generation of ROS is emerging as 
a crucial factor. The above facts provide support for the 
use of antioxidants in prevention of diabetic complica-
tions (Karasu et al., 1997, Afanasjev, 2010). 
In our previous experiments, we found impaired endo-
thelial function induced by long-lasting streptozotocin 
(STZ)-induced diabetes in rats (Sotníková et al., 1999a). 
Dietary supplementation of the pyridoindole antioxidant 
stobadine reduced this impairment (Sotníková et al., 
2001). The long-lasting hyperglycaemia had a detrimen-
tal yet reversible effect on the structure of the aorta, 
which was reduced by administration of antioxidants 
(Okruhlicová et al., 2001). 
The experimental model of STZ-induced diabetes 
was used to study the ability of the pyridoindole antioxi-
dant SMe1EC2 to prevent or delay the onset of diabetic 
vasculopathies. Diabetes was induced by STZ (30 mg/kg 
i.p.) administered for three consecutive days to male rats. 
Administration of repeated low doses of STZ is connected 
with an autoimmune process, insulitis and slow death of 
pancreatic beta-cells, a process mimicking human diabe-
tes type 1 (Lukic et al., 1991). Changes in vascular func-
tion (the aorta and SMA) and of markers of endothelial 
injury were studied after 5 and 10 weeks from the last dose 
of STZ. 
The first changes in vascular endothelial function 
could be observed 5 weeks after induction of diabetes and 
were demonstrated by increased endothelaemia (Table 1) 
and diminished endothelium-dependent relaxation of 
SMA to acetylcholine (Figure 1a). After prolonging the 
duration of diabetes to 10 weeks, the endothelial injury 
deepened and was observed also in the aorta (Zúrová et 
al. 2006). 
The reduced endothelium-dependent response can be 
mediated by several mechanisms: decreased bioavailabil-
ity of NO, impaired diffusion of NO to smooth muscle 
cells, their decreased sensitivity or increased production 
of constrictory factors produced by the endothelium 
(Dai et al., 1993). In our experiments we demonstrated 22
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decreased NO concentration in the aorta after 5 weeks 
of diabetes (Table 1) accompanied by reduced response 
o f  S M A  t o  a c e t y l c h o l i n e .  T o  f i n d  w h i c h  e n d o t h e l i a l  
factor was responsible for the reduction of acetylcholine-
induced relaxation, we incubated arterial prepartions 
with the endothelial NO synthase (eNOS) inhibitor 
L-NG-nitroarginine methyl ester (L-NAME) and with the 
cyclooxygenase inhibitor indomethacin to obtain EDHF-
dependent relaxation. In contrast to the results of Wigg et 
al. (2001), we did not find any changes in acetylcholine-
induced relaxation after blockade of the NO-signalling 
pathway and prostaglandin synthesis (Figure 1b). This 
may be explained by the fact that those authors studied 
smaller branches of SMA where EDHF plays a more 
important role.
Diabetes-induced changes in NO-availability can be 
caused by changed production of NO. Adequate NO 
production depends on intact function of eNOS, with 
sufficiency of cofactors and substrates. Depressed pro-
duction of NO can be the result of either decreased eNOS 
expression or its activity. The enzyme eNOS is localised 
in caveolae where it is coupled with caveolin-1, a 22kDa 
protein, which is a physiological inhibitor of eNOS. 
After increasing intracellular calcium concentrations 
in endothelial cells, the complex caveolin-1 with eNOS 
breaks and eNOS is activated (Garcia-Cardena et al., 1997; 
Bucci et al., 2000). Using Western blot analysis, we did 
not find changes in eNOS expression, however expression 
of caveolin-1 was increased appr. to 140% of controls 
(p<0.05). We suggest that decreased NO bioavalability 
is not a consequence of reduced eNOS expression but of 
its activity caused by increased production of caveolin-1. 
These findings are in a good agreement with results 
of Bucci et al. (2004).
Besides reduced NO production, increased inactiva-
tion of NO by ROS may participate in decreased NO 
bioavailabity. In conditions of oxidative stress, NO 
quickly reacts with superoxide creating peroxinitrite, 
which is cytotoxic for endothelial cells and oxidises 
t e t r a h y d r o b i o p t e r i n ,  a n  e s s e n t i a l  c o f a c t o r  o f  e N O S .  
Consecutively, eNOS is uncoupled and preferentially pro-
duces superoxide instead of NO (Maritim et al., 2003). 
Moreover, peroxinitrite is also metabolised to a highly 
reactive hydroxyl radical (Beckman et al., 1990), which 
contributes to diabetes-induced endothelial dysfunction 
(Dai et al., 1993). Long-lasting heperglycaemia is the most 
important factor responsible for endothelial dysfunction 
in diabetes. Cosentino et al. (2003) observed reduced 
Table 1. Effect of SMe1EC2 on endothelaemia, on basal chemilumi-
niscence and on NOx and GSH levels in the aorta after 5 weeks of 
diabetes.
Group
Endo-
thelaemia CL NOx GSH
C 2.29 ± 0.29 0.573±0.13 108.82±11.21 4.34±0.70
D 3.71 ± 0.25* 1.153±0.18 * 61.90±14.42* 1.70±0.66*
D – SMe1EC2 2.05 ± 0.51+ 0.925±0.12 89.85±5.02 2.78±0.62
C – control group, D – diabetic group, D-SMe1EC2 – diabetic rats treateted 
with SMe1EC2. Endothelaemia is expressed in the cell number/10μl blood, 
chemiluminiscence (CL) as AUC (area under the curve) in mV/min/mg aortic 
tissue, NOx  levels in nmol/mg protein, levels of reduced glutathione (GSH) in 
μg/mg protein. Results are means ± S.E.M., n= 5–9,* p<0.05 versus control. + 
p<0.05 versus diabetes
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Figure 1. Eff  ect of SMe1EC2 on endothelium-dependent relaxation of the superior mesenteric artery (SMA) ex vivo. Acetylcholine-induced 
responses of the phenylephrine (1μmol/l)-precontracted rings of SMA from control rats (C), control rats treated with 10mg/kg SMe1EC2 
(C-SMe1EC2), diabetic rats (D), diabetic rats treated with SMe1EC2 (D-SMe1EC2). A – before blockade of eNOS with L-NAME and of pros-
taglandin synthesis with indomethacin; B – after blockade of eNOS with L-NAME and of prostaglandin synthesis with indomethacin. Data 
are means±S.E.M. of 8 experiments. ***p<0.001 versus C. 23
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levels of NOx caused by incubation of endothelial cells 
in solutions containing high concentrations of glucose. 
Similarly in our in vitro experiments, incubation of the 
aorta in the solution containing high concentration of 
glucose resulted in reduced endothelium-dependent 
relaxation (Figure 2a). We suggest that this is connected 
with oxidative stress since on using CL we found increased 
ROS production in these aortic preparations (Figure 2b).
One of the sources of ROS production is activation of 
proteinkinase C (PKC), which activates NAD(P)H-oxidase 
producing high amounts of superoxide in vessels 
(Cosentino et al., 2003). NAD(P)H-oxidase is a dominant 
source of superoxide in the vessels. It is a multicomponent 
enzyme found in phagocytes, endothelial and smooth 
muscle cells and in fibroblasts of vascular adventitia. It 
consists of the main catalytic subunit gp91phox (in ves-
sels nox2) and of regulatory subunists p22phox, p47phox, 
p67phox, p40phox and GTPase Rac2. The  subunits 
gp91phox and p22phox supply the transport of electrons 
from NAD(P)H to O2. Homologues of gp91phox were 
idenitified in vessels and they are termed nox1-5. Up to 
45–56% they are identical with gp91phox (Babior, 1999). 
In our experiments, we found increased ROS production 
already after 5 weeks of diabetes (Table 1) but no changes 
in mRNA expression of subunits nox1 and nox4. One of 
the explanations could be that in the early phases of dia-
betes enzymatic NAD(P)H-oxidase activity is increased 
by accelerated association of individual components 
without increased expression of catalytic subunits. 
However Wendt et al. (2005) observed increased activity 
simultaneously with increased nox1 expression after 8 
weeks of diabetes. Another explanation could be that in 
the early phases of diabetes an increased production of 
superoxide in vessels may be the cosequence of increased 
expression of nox2 (Hink et al., 2001). It thus seems that 
individual catalytic subunits of NAD(P)H-oxidase are 
exprimed at different time intervals, in different types 
of cells and they may also possess different functions. 
While nox2 subunit is responsible for ROS production in 
endothelial cells, nox1 subunit is a source of ROS in vas-
cular smooth muscle cells. Angiotensin II increases nox1 
expression, yet it has no effet on nox4 subunit (Mollnau et 
al., 2002). On the other hand, TNF-α increases nox4 sub-
unit and does not influence nox1 expression (Moe et al., 
2006). In our experiments, we observed increased nox4 
expression when diabetes lasted a very long time, i.e. 5 
months (p<0.05), while nox1 expression was not changed. 
Moreover, nox4 expression was many times higher than 
nox1 expression. We suggest that under conditions of our 
experimental model, nox4 plays a more important role.
Oxidative stress can result also from reduced activity 
of antioxidative systems. We observed decreased levels of 
reduced glutathione (GSH) after 5 weeks of diabetes (from 
control values of 5.34 ± 0.70 to 2.70 ± 0.76 μg/mg protein, 
p<0.05) which is in agreement with results of Tachi et 
al. (2001) and Yue et al. (2003). Changes in GSH levels 
probably result from increased ROS production induced 
by hyperglycaemia, which is in accordance with the obser-
vation of GSH depletion in vascular cells incubated with a 
high concentration of glucose (Urata et al., 1996). On the 
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Figure 2. Eff  ect of SMe1EC2 on endothelial dysfunction induced by a high concentration of glucose in vitro. C – control preparations incu-
bated in Krebs solution, GLU – preparations incubated in Krebs solution containing 44 mmol/l glucose, GLU-SMe1EC2 – preparations incu-
bated in Krebs solution containing 44 mmol/l glucose and 10 μmol/l SMe1EC2. A – responses of phenylephrine (1 μmol/l)-precontracted 
rings of the aorta to acetylcholine; B – chemiluminiscence expressed as AUC (area under the curve) in mV/min/mg of wet aortic tissue. Data 
are means±S.E.M. of 6 experiments. *p<0.05, **p<0.01 versus C. 24
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other hand, after 10 weeks of diabetes GSH concentration 
in the aorta was not changed (Zúrová-Nedelčevová et 
al., 2006). We propose that unchanged GSH levels in the 
aorta may reflect adaptation of the organism to chronic 
oxidative stress in the later phase of diabetes. 
Eff  ect of SMe1EC2
On using the described experimental model, an endo-
thelium-protective effect of the antioxidant stobadine 
was observed. This finding confirmed the assumption of 
the important role of ROS in aetiopathology of diabetes-
induced endothelial dysfunction (Sotníková et al., 2006a). 
I n  t h e  s a m e  m o d e l  o f  S T Z - d i a b e t e s ,  w e  f u r t h e r  
studied the effect of the stobadine derivative SMe1EC2 
administered in the dose of 10 mg/kg every second day. A 
beneficial effect of SMe1EC2 on the vascular endothelium 
was found in our in vitro experiments, in which the aortal 
rings were incubated in a solution with a high concentra-
tion of glucose. The decreased endothelium-dependent 
relaxation was restored by this antioxidant (Figure 2). 
Searching for possible mechanisms of the SMe1EC2 pro-
tective effect, we found that it had no effect on basal tone 
of the arterial preparations or on contraction induced by 
depolarisation. It did not influence the concentration-
response curves of phenylephrine or serotonin, indicat-
ing no effect on α1-adrenergic or 5-hydroxytryptamine 
receptors. Moreover, SMe1EC2 did not affect responses 
of the isolated aorta to the M3-agonist acetylcholine. Thus 
we propose that the endothelium-protective effect of 
SMe1EC2 is mediated by its antioxidant activity found also 
in the 1,1-diphenyl-2-picrylhydrazyl radical – (DPPH) test 
(Nosáľová et al., 2010). With pD2 value of 5.67, SMe1EC2 
exhibited a DPPH radical-scavenging activity higher 
than did stobadine. Indeed, under in vitro conditions, 
this compound suppressed production of ROS evoked by 
mesenteric I/R (Nosáľová et al., 2010) and significantly 
reduced contraction of the aorta induced by ROS released 
from activated neutrophils (Bauer et al., 2008) (Figure 3).
We further found that in vivo administration of 10 
mg/kg SMe1EC2 protected endothelial function. It 
significantly decreased endothelaemia of diabetic rats 
(Table 1) and improved endothelium-dependent relax-
ation of the aorta (Zúrová-Nedelčevová et al., 2006) and 
SMA without effect on the EDHF component (Figure 1). 
Therefore we assumed that this compound affected the 
NO-signalling pathway. Administration of SMe1EC2 
slightly increased biological availability of NO in the 
aorta (Table 1), but it did not influence expression of 
eNOS or of caveolin-1. One of the explanations is that by 
its antioxidant properties SMe1EC2 inactivated ROS and 
thus increased NO bioavalability. This assumption was 
based also on the results of our in vitro experiments in 
which this compound intensively reduced CL increased 
by high glucose incubation and simultaneously protected 
endothelium-dependent relaxation of the aorta (Figure 2). 
In in vivo conditions, we observed a tendency of SMe1EC2 
to decrease spontaneous ROS production and to increase 
levels of GSH in the aorta of diabetic rats (Table 1). These 
results may indicate that the dose of 10 mg/kg SMe1EC2 
was not sufficient to observe all antioxidant properties 
in vivo. Further studies with higher doses of SMe1EC2 
may clarify the mechanism of its endothelium-protective 
effect in STZ-diabetes in rats. 
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Figure 3. Eff  ect of SMe1EC2 on the contraction induced by 
activated neutrophils in vitro. Responses of phenylephrine 
(1    μmol/l)-precontracted rings of the rat aorta to FMLP 
(N-formyl-methionyl-leucyl-phenylalanine, 10-7 mol/l)-activated 
neutrophils (106/ml). C – control rings, SMe1EC2 – rings pre-
treated with 10μmol/l SMe1EC2. Data are means±S.E.M. of 12 
experiments. ***p<0.001 versus C. 
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